Details: pack, label wording, sources, registration
Hepatiale Forte Advanced, Tablet
tablet, VetExpert
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy
5.3/10
Weak evidence support
Details →
vetman assessment
Hepatiale Forte Advanced
×
tablet, VetExpert
Assessed clinical scope Dog · Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy · By mouth
Care setting Veterinarian-directed outpatient adjunct with exact-form dose review, concurrent-product screening and objective reassessment.
vetman score
5.3/10
Weak evidence support
Evidence confidence: Low
Georgia: Not a medicine · Verified on 22 Oct 2026
The strongest Hepatiale record because an exact-product dog pilot exists, but its uncontrolled sponsor-linked biomarker result and schedule mismatch still leave overall value weak.
Regulatory and scientific credibility 5.0/10
Exact transparent composition and a current peer-reviewed exact-product pilot improve traceability, but complementary-feed oversight, open-label design and manufacturer conflicts leave credibility moderate.
Clinical efficacy 4.5/10
The 17-dog open-label pilot found improved liver biomarkers after eight weeks, but no control, small heterogeneous sample, sponsor involvement and no patient-centred or durable outcomes prevent a causal efficacy claim.
Safety and tolerability 6.0/10
Seventeen dogs completed eight weeks without reported adverse effects, supporting short-term tolerability only; no controlled frequency estimate, long-term, reproductive or severe-disease safety is available.
Clinical practicality 6.0/10
Oral administration is manageable, but the every-other-day to daily transition at 10 kg and mismatch between the current low-weight label and the pilot regimen require careful schedule selection.
Full-course cost-effectiveness -
No verified current Georgian patient-adjusted course price or evidence-based treatment duration is available, so cost is excluded.
Important safety and use flags
Complementary feed, not a medicine. Medicine-authorisation status is not applicable; this category neither proves nor disproves clinical efficacy. Adjunct only after diagnosis and disease-specific care. Do not substitute this product for indicated diet, antidote, antimicrobial, immunosuppression, copper management, biliary intervention or other treatment. The exact Advanced dog study was open-label, uncontrolled, small and manufacturer-linked, and measured mainly biomarkers. It does not prove regeneration, fibrosis reversal, survival benefit or durable disease control. Do not transfer efficacy, safety or dose from another Hepatiale presentation, another phospholipid/silymarin formulation, human studies or intravenous studies. The 2026 dog pilot used one tablet/10 kg daily, while the current page gives animals up to 10 kg one tablet every other day. Do not claim that the trial validates the current low-weight or feline schedule. Biochemical improvement is not equivalent to a patient-centred outcome. Define the intended clinical objective and a reassessment/stop point before starting. No regulator-grade adverse-event frequency or contraindication section is available. Review soy sensitivity, GI tolerance, age, severe organ disease and every concurrent medicine or supplement; Advanced also contains milk thistle and zinc. Avoid duplicate hepatoprotective ingredients and review polypharmacy. Native extracts and multi-ingredient products are not automatically interchangeable, and interaction magnitude is not established for the exact product. Monitor the diagnosed disease objectively with clinical status, appetite, weight and condition-appropriate liver biochemistry, imaging or histology. Stop or revise the plan if no defined benefit appears or disease progresses. Exact safety in pregnancy, lactation, breeding animals, neonates and long-term severe hepatic, renal or multisystem disease is not established; use only after explicit individual benefit-risk review. Assessment sources +
Close
Cat
Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy
4.3/10
Weak evidence support
Details →
vetman assessment
Hepatiale Forte Advanced
×
tablet, VetExpert
Assessed clinical scope Cat · Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy · By mouth
Care setting Veterinarian-directed outpatient adjunct with exact-form dose review, concurrent-product screening and objective reassessment.
vetman score
4.3/10
Weak evidence support
Evidence confidence: Low
Georgia: Not a medicine · Verified on 22 Oct 2026
A transparent complementary feed with workable label administration but no exact feline outcome evidence; use only as a monitored adjunct, not a treatment substitute.
Regulatory and scientific credibility 4.5/10
Exact composition and category are transparent, but the only exact-product peer-reviewed trial is canine, open-label and manufacturer-linked; no feline dossier or trial supports the assessed species.
Clinical efficacy 3.0/10
Advanced has a small positive dog pilot but no feline outcome study; canine biomarkers and ingredient mechanisms do not validate the current feline schedule or clinical benefit.
Safety and tolerability 4.5/10
No exact feline target-animal safety study or adverse-event frequency is available. Manufacturer silence cannot prove safety; soy, GI tolerance, concurrent supplements and product-specific ingredients require review.
Clinical practicality 5.5/10
A whole tablet every other day avoids fractional dosing for cats up to 10 kg, but no schedule exists above that boundary and the canine daily pilot does not validate feline administration.
Full-course cost-effectiveness -
No verified current Georgian patient-adjusted course price or evidence-based treatment duration is available, so cost is excluded.
Important safety and use flags
Complementary feed, not a medicine. Medicine-authorisation status is not applicable; this category neither proves nor disproves clinical efficacy. Adjunct only after diagnosis and disease-specific care. Do not substitute this product for indicated diet, antidote, antimicrobial, immunosuppression, copper management, biliary intervention or other treatment. The exact Advanced dog study was open-label, uncontrolled, small and manufacturer-linked, and measured mainly biomarkers. It does not prove regeneration, fibrosis reversal, survival benefit or durable disease control. Do not transfer efficacy, safety or dose from another Hepatiale presentation, another phospholipid/silymarin formulation, human studies or intravenous studies. The 2026 dog pilot used one tablet/10 kg daily, while the current page gives animals up to 10 kg one tablet every other day. Do not claim that the trial validates the current low-weight or feline schedule. No exact-product feline clinical outcome study was located. Canine biomarker results and ingredient mechanisms cannot establish feline benefit or target-animal safety. No regulator-grade adverse-event frequency or contraindication section is available. Review soy sensitivity, GI tolerance, age, severe organ disease and every concurrent medicine or supplement; Advanced also contains milk thistle and zinc. Avoid duplicate hepatoprotective ingredients and review polypharmacy. Native extracts and multi-ingredient products are not automatically interchangeable, and interaction magnitude is not established for the exact product. Monitor the diagnosed disease objectively with clinical status, appetite, weight and condition-appropriate liver biochemistry, imaging or histology. Stop or revise the plan if no defined benefit appears or disease progresses. Exact safety in pregnancy, lactation, breeding animals, neonates and long-term severe hepatic, renal or multisystem disease is not established; use only after explicit individual benefit-risk review. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
EU
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
UK
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
US
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
Current manufacturer schedule: cats and dogs up to 10 kg, one tablet every other day; dogs over 10 kg, one tablet per 10 kg once daily. The 2026 dog pilot used one tablet per 10 kg daily, so its results do not directly validate the current low-weight or feline schedule.
Dose Species Weight Route Frequency Source
1 tablet
Current label schedule for cats up to and including 10 kg; no exact feline outcome study validates it.
Cat
up to 10 kg
By mouth
every other day
VetExpert Advanced
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Hepatiale Forte Advanced - current exact product composition and use instructions
VetExpert product information, 2026
1 tablet
Current label schedule for dogs up to and including 10 kg. The 2026 pilot used a different once-daily 1 tablet/10 kg regimen.
Dog
up to 10 kg
By mouth
every other day
VetExpert Advanced
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Hepatiale Forte Advanced - current exact product composition and use instructions
VetExpert product information, 2026
1 tablet per 10 kg
Current label schedule for dogs over 10 kg. The lower boundary is exclusive and does not overlap the inclusive low-weight band.
Dog
over 10 kg
By mouth
once daily
VetExpert Advanced
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Hepatiale Forte Advanced - current exact product composition and use instructions
VetExpert product information, 2026
